Estimation of influence of the complex therapy of pregnant women with fetal growth delay on biochemical homeostasis state and delivery results

Abstract

Fetal growth delay (FGD) can be the result of maternal, placental, embryonal and genetic reason and also various combination of any variants [1, 3]. During pregnancy the placental insufficiency (PI) is the most often reason for abnormalities of the fetus state and the main reason for FGD. FGD is not independent nosological form but the sum of abnormalities of the fetus state due to changes of metabolic processes in fetoplacental complex [2, 7]. Diagnostics of FGD is the one of the most complicated in obstetrics. Thus, all pregnant women should have meticulous clinical, instrumental and laboratory examination. These methods solve different tasks but in complex they give the maximum information as to the fetus state [1]. Despite the numerous researches of FGD problem the search of new methods for diagnostics as well as treatment of the present pathology lasts until now. Thus in many foreign and national researches it was found that the effective therapy of FGD syndrome is absent today. However it is possible to maintain metabolic processes at appropriate level and slow down further progress of complications [5]. Such pharmacotherapy can include medicines which have effect on uterus muscles and tocolytic effect; medicines which improve micro-circulation and blood rheological properties; medicines which increase resistance of the fetus brain and tissues against hypoxia [6].